Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO2LE6
|
|||
| Drug Name |
CC-31244
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Cocrystal Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02760758) A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cocrystal Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.